高频超声评价罗格列酮对2型糖尿病动脉内皮功能的影响

Evaluation of the Effect of Rosiglitazone on Endothelium Function of Aorta in Type 2 Diabetes by High-Frequency Ultrasound

【目的】观察噻唑烷二酮类药物罗格列酮对2型糖尿病患者肱动脉血流介导内皮舒张功能的影响。【方法】43例2型糖尿病病人分为罗格列酮(4mg/d)治疗组和常规治疗组,治疗前及治疗3个月后分别测体重指数(BMI)、血压、空腹血糖、血脂、尿微量白蛋白及高频超声测量肱动脉血流介导的血管活性(FMD)和硝酸甘油介导的血管活性(NTGMD)。【结果】罗格列酮治疗后血压降低,尿微量白蛋白亦明显降低,肱动脉血流介导的血管活性(FMD)明显改善(P<0.01),而硝酸甘油介导的血管活性无明显变化。【结论】罗格列酮可改善内皮依赖性舒张功能,有利于血压降低和尿微量白蛋白减少。

[Objective]To evaluate the effect of rosiglitazone on brachial artery endothelial function. [Methods]Forty three type 2 diabetes patients were divided into rosiglitazone group（receiving 4mg rosiglitazone once a day） and control group （receiving conventional treatment）. Flow mediated dilation （FMD） and nitroglycerine mediated dilation （NTGMD） in the right brachial artery was evaluated by high-frequency ultrasound before and after taking rosiglitazone for 3 months. BMI, blood pressure, blood lipid and urine albumin were measured. [Results] Compared with control group, blood pressure and urine albumin decreased significantly, and FMD improved significantly in rosiglitazone group, but there was no significant difference in the change of NTGMD between the two groups. [Conclusion]Rosiglitazone can significantly improve the endothelial function, and alleviate the blood pressure and urine albumin in the patients with type 2 diabetes.